-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$44.3330.54% Upside
PTC Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover PTC Therapeutics, Inc.?
PTC Therapeutics, Inc. has been rated by research analysts at UBS, Morgan Stanley, Goldman Sachs, Jefferies, RBC Capital, Cantor Fitzgerald in the past 90 days.